SG10201907660YA - Use of short chain fatty acids in cancer prevention - Google Patents
Use of short chain fatty acids in cancer preventionInfo
- Publication number
- SG10201907660YA SG10201907660YA SG10201907660YA SG10201907660YA SG 10201907660Y A SG10201907660Y A SG 10201907660YA SG 10201907660Y A SG10201907660Y A SG 10201907660YA SG 10201907660Y A SG10201907660Y A SG 10201907660YA
- Authority
- SG
- Singapore
- Prior art keywords
- fatty acids
- chain fatty
- short chain
- compositions
- cancer prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Non-Alcoholic Beverages (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562106778P | 2015-01-23 | 2015-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201907660YA true SG10201907660YA (en) | 2019-10-30 |
Family
ID=56417737
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201907660Y SG10201907660YA (en) | 2015-01-23 | 2016-01-21 | Use of short chain fatty acids in cancer prevention |
| SG11201705953XA SG11201705953XA (en) | 2015-01-23 | 2016-01-21 | Use of short chain fatty acids in cancer prevention |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201705953XA SG11201705953XA (en) | 2015-01-23 | 2016-01-21 | Use of short chain fatty acids in cancer prevention |
Country Status (12)
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| EP4529950A3 (en) | 2014-10-31 | 2025-08-20 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment |
| DK3193901T3 (en) | 2014-12-23 | 2018-05-28 | 4D Pharma Res Ltd | PIRIN POLYPEPTIDE AND IMMUNMODULATION |
| PE20171138A1 (es) | 2014-12-23 | 2017-08-09 | 4D Pharma Res Ltd | Modulacion inmunitaria |
| PE20180243A1 (es) | 2015-06-15 | 2018-01-31 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| EP3662917A1 (en) | 2015-06-15 | 2020-06-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| LT3360559T (lt) | 2015-06-15 | 2019-12-27 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterijų kamienus |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MA41013A (fr) | 2015-11-20 | 2017-08-30 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MX373290B (es) | 2016-03-04 | 2020-06-18 | 4D Pharma Plc | Composiciones que comprenden cepas bacterianas. |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| WO2018089861A1 (en) * | 2016-11-11 | 2018-05-17 | The Regents Of The University Of California | Methods and compositions for the treatment of cancer and metabolic diseases |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| CN110475551A (zh) | 2017-01-27 | 2019-11-19 | 英联邦高等教育系统天普大学 | 使用短链脂肪酸治疗和预防疾病和障碍 |
| WO2018195067A1 (en) | 2017-04-17 | 2018-10-25 | The University Of Chicago | Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease |
| US20220304967A1 (en) * | 2017-04-24 | 2022-09-29 | Allerpops | Oral microbiota promoting composition cross-reference to related applications |
| MA48940A (fr) | 2017-05-22 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41708A (fr) | 2017-05-24 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| PL3638271T3 (pl) | 2017-06-14 | 2021-03-22 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
| JP2020523326A (ja) | 2017-06-14 | 2020-08-06 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| TWI767013B (zh) | 2017-06-14 | 2022-06-11 | 英商4D製藥研究有限公司 | 包含細菌品系之組成物 |
| KR102563191B1 (ko) | 2017-07-05 | 2023-08-02 | 에벨로 바이오사이언시즈, 인크. | 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법 |
| EP3661371A1 (en) * | 2017-08-04 | 2020-06-10 | Société des Produits Nestlé S.A. | Probiotic bacteria preconditioned in a gos-containing medium and use thereof |
| WO2019046646A1 (en) | 2017-08-30 | 2019-03-07 | Whole Biome Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
| CN110090230B (zh) * | 2018-01-30 | 2022-07-12 | 青岛东海药业有限公司 | 凝结芽孢杆菌在制备预防或治疗胆管癌制剂中的应用 |
| LT3743086T (lt) * | 2018-05-11 | 2022-06-10 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterinius kamienus |
| SG11202011817WA (en) * | 2018-06-01 | 2020-12-30 | Evolve Biosystems Inc | Compositions and methods to promote host defense and stimulate, expand, and/or reset t cell repertoires |
| CN113164526A (zh) | 2018-07-19 | 2021-07-23 | 潘德勒姆治疗公司 | 用于微生物植入的方法和组合物 |
| AU2020355194B2 (en) * | 2019-09-25 | 2026-06-18 | Julius-Maximilians-Universität Würzburg | Short-chain fatty acid pentanoate as enhancer for cellular therapy and anti-tumor therapy |
| KR102510198B1 (ko) * | 2019-11-14 | 2023-03-15 | 가톨릭대학교 산학협력단 | 락토바실러스 속 균주 및 SCFA(Short fatty chain acid)를 포함하는 면역 질환의 예방 및 치료용 조성물 |
| TWI734341B (zh) * | 2020-01-14 | 2021-07-21 | 景岳生物科技股份有限公司 | 一種副乾酪乳桿菌ｇｍｎｌ-３４６用於抗口腔癌之用途 |
| EP4134089A1 (en) * | 2020-03-05 | 2023-02-15 | Liscure Biosciences Co., Ltd. | Pharmaceutical composition comprising genus leuconostoc strain as active ingredient for prevention or treatment of cancer |
| WO2022031787A1 (en) * | 2020-08-04 | 2022-02-10 | Temple University-Of The Commonwealth System Of Higher Education | Methods and compositions for treating cytokine release syndrome |
| US11938152B2 (en) | 2020-08-06 | 2024-03-26 | Kedar N Prasad | High-dose antioxidants in cancer treatment |
| US20240009155A1 (en) * | 2020-11-12 | 2024-01-11 | Temple University-Of The Commonwealth System Of Higher Education | Use of short chain fatty acids in cancer prevention |
| WO2022177409A1 (ko) * | 2021-02-22 | 2022-08-25 | 주식회사 리스큐어바이오사이언시스 | 류코노스톡 메센테로이데스 균주 유래 나노소포체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 |
| KR102942263B1 (ko) * | 2021-11-05 | 2026-03-23 | 건국대학교 글로컬산학협력단 | 하이칸톤을 포함하는 우울장애 또는 신경염증질환의 예방 또는 치료용 조성물 |
| CA3249056A1 (en) * | 2022-01-19 | 2023-07-27 | Ian Hodgdon | SHORT CHAIN FATTY ACIDS FOR CANCER TREATMENT |
| CN117925434B (zh) * | 2022-10-26 | 2025-02-14 | 慕恩（广州）生物科技有限公司 | 粪肠球菌mnh 22871及其应用 |
| CN116212027A (zh) * | 2023-02-28 | 2023-06-06 | 西湖大学 | 一种调控Treg细胞内铁水平的试剂的用途 |
| AU2024405251A1 (en) | 2023-12-22 | 2026-07-09 | Temple University-Of The Commonwealth System Of Higher Education | Short chain fatty acid compounds and uses thereof |
| WO2025176152A1 (en) * | 2024-02-19 | 2025-08-28 | The University Of Hong Kong | Probiotics mixtures and methods of use thereof for treating cancers |
| CN119424400B (zh) * | 2024-10-21 | 2026-03-03 | 江南大学 | 缓解衰老的肠道菌群支链氨基酸代谢产物异丁酸和异戊酸及其应用 |
| CN119258047A (zh) * | 2024-11-26 | 2025-01-07 | 哈尔滨医科大学 | 琥珀酸在制备防治肝癌药物中的新用途 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4735967A (en) | 1985-05-28 | 1988-04-05 | Neesby Torben E | Method for desensitizing the gastrointestinal tract from food allergies |
| AU645070B2 (en) | 1990-04-10 | 1994-01-06 | Nb International Technologies | Use of short chain fatty acid containing lipids to maintain gastrointestinal integrity and function in patients DO NOT SEAL - SEE LETTER DATED 22.03.94 |
| PH31403A (en) | 1991-03-01 | 1998-10-29 | Warner Lambert Co | Therapeutic compositions to protect and recuscitate mammalian cells and methods for preparing same. |
| WO1995011699A1 (en) | 1993-10-29 | 1995-05-04 | The Trustees Of Boston University | Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents |
| JP2000072667A (ja) | 1998-08-25 | 2000-03-07 | Kurasuraa:Kk | 大腸炎治療用経口投与剤 |
| US6201077B1 (en) | 1998-12-01 | 2001-03-13 | Phillips Petroleum Company | Process that produces polymers |
| EP1034788A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactic acid bacteria strains capable of preventing diarrhea |
| JP4360915B2 (ja) | 2002-01-07 | 2009-11-11 | ユーロスクリーン・ソシエテ・アノニム | Ｇタンパク質共役受容体ｇｐｒ４３のリガンドおよびその使用 |
| MXPA04008577A (es) | 2002-03-04 | 2005-07-13 | Aton Pharma Inc | Metodos para inducir diferenciacion terminal. |
| JP2005530734A (ja) | 2002-04-15 | 2005-10-13 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 癌の処置のための併用療法 |
| US8846039B2 (en) | 2002-04-26 | 2014-09-30 | Asan Laboratories Company (Cayman), Limited | Method for ameliorating pruritus |
| CN1681505A (zh) | 2002-09-13 | 2005-10-12 | 弗吉尼亚州立大学 | 用于治疗白血病的а ) N－{ 5－[ 4－( 4－甲基－哌嗪－1－基－甲基)－苯甲酰氨基]－2－甲基苯基}－4－( 3－吡啶基 ) －2－嘧啶－胺和b )组蛋白脱乙酰基酶抑制剂的组合 |
| US20050023179A1 (en) | 2003-07-31 | 2005-02-03 | Albritton Charles Wade | Fragile-product cage for vacuum packaging appliances |
| CN102349927A (zh) | 2003-08-29 | 2012-02-15 | Hdac默克研究有限责任公司 | 联合治疗癌症的方法 |
| WO2007016953A1 (en) | 2005-07-29 | 2007-02-15 | Matuschka-Greiffenclau Markus | Composition for reducing alcohol induced liver cancer risk |
| EP2389930A1 (en) * | 2006-03-31 | 2011-11-30 | Erasmus University Medical Center Rotterdam | Novel composition for tumor growth control |
| WO2008054293A1 (en) * | 2006-11-03 | 2008-05-08 | Salutary Care Limited | Composition, its use for treating systemic diseases a conditions, and product containing said composition |
| US20080153908A1 (en) | 2006-12-20 | 2008-06-26 | Jani Dharmendra M | Method of Treating Mucin Deficiency with an Active Pharmaceutical and Related Composition |
| US9078864B2 (en) | 2008-01-08 | 2015-07-14 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| CN101214234B (zh) | 2008-01-10 | 2010-09-08 | 中国人民解放军第二军医大学 | α-羟基酸在制备癌瘤体内注射治疗药物中的应用 |
| EP2398444A4 (en) | 2009-02-18 | 2015-06-17 | Sea Qiq As | MIXTURE FROM INORGANIC COMPOUNDS, PREPARATIONS WITH THE MIXTURE AND USE OF THE MIXTURE |
| EP3181134B1 (en) | 2009-06-19 | 2019-10-30 | DuPont Nutrition Biosciences ApS | Bifidobacteria for treating diabetes and related conditions |
| US8962686B2 (en) | 2010-04-28 | 2015-02-24 | The Chinese University Of Hong Kong | Method and medication for prevention and treatment of ocular hypertension and glaucoma |
| EP2389932A1 (en) | 2010-05-28 | 2011-11-30 | Lunamed AG | Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts |
| US20130115280A1 (en) | 2010-07-29 | 2013-05-09 | Cosmo Technologies Ltd | Pharmaceutical and/or dietary compositions based on sort chain fatty acids |
| SG183544A1 (en) | 2010-11-29 | 2012-10-30 | Univ Putra Malaysia | Tumour cytotoxic agent and methods thereof |
| CN111518866A (zh) * | 2011-03-01 | 2020-08-11 | 群体创新有限责任公司 | 用于治疗与致病生物膜相关之病症的材料和方法 |
| WO2012131069A1 (en) | 2011-03-31 | 2012-10-04 | Proponent Biotech Gmbh | Short chain fatty acids and their derivatives for use in treatment immunogenic disorders |
| WO2012145684A1 (en) * | 2011-04-22 | 2012-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Transient hypoxia inducers and their use |
| SG10202013014RA (en) * | 2012-01-16 | 2021-02-25 | Mckenna Elizabeth | Compositions and Methods for the Treatment of Hepatic Diseases and Disorders |
| GB201215289D0 (en) | 2012-08-28 | 2012-10-10 | Medical Res Council | Nanoparticle formulation |
| TWI463986B (zh) | 2012-08-29 | 2014-12-11 | Univ China Medical | 胚芽乳酸桿菌ｃｍｕ９９５菌株之新用途 |
| TWI472324B (zh) * | 2013-05-14 | 2015-02-11 | 應用二甲雙胍與丁酸鈉於ｋｒａｓ基因突變癌症治療之用途、醫藥組合物與醫藥套組 | |
| US9764019B2 (en) | 2013-07-09 | 2017-09-19 | Vedanta Biosciences, Inc. | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease |
| EP3033091B1 (en) * | 2013-08-16 | 2022-09-07 | Versitech Limited | Probiotic composition and use thereof in the prevention and treatment of hepatocellular carcinoma |
-
2016
- 2016-01-21 SG SG10201907660Y patent/SG10201907660YA/en unknown
- 2016-01-21 RU RU2017127597A patent/RU2017127597A/ru not_active Application Discontinuation
- 2016-01-21 WO PCT/US2016/014292 patent/WO2016118730A1/en not_active Ceased
- 2016-01-21 AU AU2016209244A patent/AU2016209244A1/en not_active Abandoned
- 2016-01-21 US US15/545,371 patent/US10231941B2/en active Active
- 2016-01-21 KR KR1020177023391A patent/KR102735818B1/ko active Active
- 2016-01-21 EP EP26150406.2A patent/EP4748449A3/en active Pending
- 2016-01-21 EP EP16740745.1A patent/EP3247342B1/en active Active
- 2016-01-21 MX MX2017009532A patent/MX387817B/es unknown
- 2016-01-21 JP JP2017557279A patent/JP6783247B2/ja active Active
- 2016-01-21 CN CN201680017250.3A patent/CN107405321A/zh active Pending
- 2016-01-21 SG SG11201705953XA patent/SG11201705953XA/en unknown
- 2016-01-21 CN CN202210967776.5A patent/CN115350171A/zh active Pending
-
2017
- 2017-07-19 IL IL253581A patent/IL253581A0/en active IP Right Grant
- 2017-07-21 ZA ZA2017/04977A patent/ZA201704977B/en unknown
-
2018
- 2018-02-23 US US15/903,395 patent/US10143669B2/en active Active
-
2019
- 2019-01-30 US US16/261,836 patent/US20190160031A1/en not_active Abandoned
- 2019-03-15 AU AU2019201799A patent/AU2019201799B2/en active Active
-
2020
- 2020-09-23 AU AU2020239699A patent/AU2020239699A1/en not_active Abandoned
- 2020-10-21 JP JP2020176442A patent/JP2021020929A/ja active Pending
-
2021
- 2021-07-19 US US17/379,305 patent/US11963938B2/en active Active
-
2022
- 2022-12-08 JP JP2022196339A patent/JP2023027219A/ja active Pending
-
2024
- 2024-03-19 US US18/609,070 patent/US20240342122A1/en active Pending
- 2024-12-10 US US18/975,514 patent/US20250213508A1/en active Pending
- 2024-12-17 JP JP2024220908A patent/JP2025038120A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017009532A (es) | Uso de acidos grasos de cadena corta en prevencion de cancer. | |
| PH12021550756A1 (en) | Compositions and methods for treating and/or preventing cardiovascular disease | |
| ZA202206806B (en) | Benzooxazole derivatives as immunomodulators | |
| WO2018112365A3 (en) | Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii | |
| MX2018005600A (es) | Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello. | |
| PH12018500659A1 (en) | Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof | |
| SG10201907164SA (en) | Rna containing composition for treatment of tumor diseases | |
| MY188879A (en) | Glycan therapeutics and related methods thereof | |
| MX2018002543A (es) | Composiciones que comprenden compuestos de urolitina. | |
| EP4289820A3 (en) | Compounds for use in treating alzheimer's disease in apoe4+/+ patients | |
| SG10201806854XA (en) | Compositions comprising 15-ohepa and methods of using the same | |
| TR201908639T4 (tr) | Dejeneratif göz bozukluklarının önlenmesi ve veya tedavisine yönelik safran bazlı bileşimler. | |
| EP3581653A3 (en) | Methods and compositions for treating cancer using peptide nucleic acid-based agents | |
| SG10201805890QA (en) | Compositions and methods for treatment of abnormal cell growth | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
| PH12016501838A1 (en) | Compounds and their methods of use | |
| WO2015140798A3 (en) | Ostreolysin, functionally related variant thereof, extract comprising ostreolysin and uses thereof | |
| PH12017500203A1 (en) | Nutritional composition for use in promoting gut and/or liver maturation and/or repair | |
| MX2019004179A (es) | Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer. | |
| MX383947B (es) | Composiciones de colágeno 7 y métodos para usar las mismas. | |
| MX2019009293A (es) | Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos. | |
| WO2017004274A3 (en) | Compositions and methods of rit1 inhibition | |
| WO2017011559A8 (en) | Compositions and methods for treating cancer | |
| PH12017501693A1 (en) | Compositions for the treatment of kidney and/or liver diseases | |
| HK40020769A (en) | Composition for use in the prevention and in the treatment of iron deficiency |